Phase III Trial Shows Veracyte's Decipher Prostate Test Can Predict Benefit from Adding Abiraterone to Treatment in Very High-Risk Prostate CancerGlobeNewsWire · 2 days ago
Will Veracyte (VCYT) Beat Estimates Again in Its Next Earnings Report?Zacks Investment Research · 4 days ago
Veracyte (NASDAQ:VCYT) Stock Price Breaks Below 200 Day Moving Average – Should You Sell?Defense World · 5 days ago
Six Studies to Highlight Veracyte's Genomic Tests Across Breast, Prostate and Bladder Cancer at ESMO 2026GlobeNewsWire · 6 days ago
Veracyte Secures Medicare Reimbursement for Prosigna Breast Risk of Recurrence TestGlobeNewsWire · Oct 16, 2026
Veracyte to Release Third Quarter 2026 Financial Results on November 4, 2026GlobeNewsWire · Oct 14, 2026Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services.
| Date | Est. | Actual | |
|---|---|---|---|
| Jul 30, 2026 | $0.41 | $0.54 | Beat |
| May 5, 2026 | $0.34 | $0.52 | Beat |
| Feb 25, 2026 | $0.41 | $0.53 | Beat |
| Nov 4, 2025 | $0.32 | $0.51 | Beat |
| Aug 6, 2025 | $0.31 | $0.44 | Beat |
| May 7, 2025 | $0.12 | $0.31 | Beat |